KR20190021180A - 퇴행성 신경질환 치료용 복합 제형 조성물 - Google Patents

퇴행성 신경질환 치료용 복합 제형 조성물 Download PDF

Info

Publication number
KR20190021180A
KR20190021180A KR1020180097501A KR20180097501A KR20190021180A KR 20190021180 A KR20190021180 A KR 20190021180A KR 1020180097501 A KR1020180097501 A KR 1020180097501A KR 20180097501 A KR20180097501 A KR 20180097501A KR 20190021180 A KR20190021180 A KR 20190021180A
Authority
KR
South Korea
Prior art keywords
disease
sustained
inhibitor
present
neurodegenerative diseases
Prior art date
Application number
KR1020180097501A
Other languages
English (en)
Korean (ko)
Inventor
홍지만
임태성
최문희
Original Assignee
아주대학교산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아주대학교산학협력단 filed Critical 아주대학교산학협력단
Publication of KR20190021180A publication Critical patent/KR20190021180A/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020180097501A 2017-08-22 2018-08-21 퇴행성 신경질환 치료용 복합 제형 조성물 KR20190021180A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170105978 2017-08-22
KR1020170105978 2017-08-22

Publications (1)

Publication Number Publication Date
KR20190021180A true KR20190021180A (ko) 2019-03-05

Family

ID=65439032

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020180097501A KR20190021180A (ko) 2017-08-22 2018-08-21 퇴행성 신경질환 치료용 복합 제형 조성물

Country Status (2)

Country Link
KR (1) KR20190021180A (fr)
WO (1) WO2019039836A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022089598A1 (fr) * 2020-10-30 2022-05-05 杭州拉林智能科技有限公司 Composé de sel double de glycoside flavonoïde-amine organique neuroagoniste, son procédé de préparation et son application

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1121104E (pt) * 1998-10-01 2005-05-31 Novartis Ag Novas formulacoes orais de libertacao controlada
CN1520818A (zh) * 2003-02-09 2004-08-18 山东绿叶天然药物研究开发有限公司 治疗老年性痴呆的胆碱酯酶抑制剂药物组合物
TW201422254A (zh) * 2012-11-21 2014-06-16 Ferring Bv 用於速釋及延釋的組成物
US8999393B1 (en) * 2013-01-09 2015-04-07 Edgemont Pharmaceuticals Llc Sustained release formulations of lorazepam
KR101811700B1 (ko) * 2016-10-13 2017-12-22 한국유나이티드제약 주식회사 레보드로프로피진 함유 서방정 및 이의 제조방법

Also Published As

Publication number Publication date
WO2019039836A2 (fr) 2019-02-28
WO2019039836A3 (fr) 2019-04-18

Similar Documents

Publication Publication Date Title
US9913836B2 (en) Anticholinergic neuroprotective composition and methods
US9044472B2 (en) Use and composition for treating dementia
JP6226916B2 (ja) 医薬組成物
NZ565840A (en) Therapy for the treatment of disease
WO2000015205A2 (fr) Utilisation d'inhibiteurs acetylcholinesterases pour la preparation de compositions pharmaceutiques destinees au traitement de syndromes de douleur fonctionnelle et/ou organique
US20120122919A1 (en) Pharmaceutical composition combining tenatoprazole and a histamine h2-receptor antagonist
KR20190021180A (ko) 퇴행성 신경질환 치료용 복합 제형 조성물
US7872035B2 (en) Angiotensin II antagonists
AU2001274765A1 (en) New use of angiotensin II antagonists
CN112912076A (zh) 氨基甲酸酯化合物用于预防、缓解或治疗糖尿病性周围神经病变或化疗诱发性周围神经病变的用途
US20220362202A1 (en) Drug For Treating And Preventing Dementia
JP2024505246A (ja) 神経変性認知障害を治療するための、コリンエステラーゼ阻害薬と四級アンモニウム抗ムスカリン剤との固定用量配合剤
KR20150044953A (ko) 이피다크린을 포함하는 약제학적 조성물과 성기능 장애 및 다른 형태의 성활동의 장애의 치료를 위한 그의 용도
EP0818997A1 (fr) Compositions comprenant l'amiodarone et le betaxolol
HUE025669T2 (en) Pharmaceutical preparations containing beta and alpha-galactosidase and their use in the treatment of gastroesophageal reflux disease

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application